Janet Lasher

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Roelf Valkema, Stanislas Pauwels, Larry K. Kvols et al. · PubMed · 2005 · 334 citations · Full text

Medicine, Nuclear Medicine, Oncology +16

A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy

David G. Maloney, Michinori Ogura, Noriko Fukuhara et al. · Blood Advances · 2020 · 34 citations · Full text

Medicine, Immunology, Oncology +13

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study

Stephan Petersenn, Jens Bollerslev, Ayman M. Arafat et al. · The Journal of Clinical Pharmacology · 2014 · 31 citations

Medicine, Endocrinology, Pharmacology +13

Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers: A Single-Center, Open-Label, Ascending-Dose Study

Stephan Petersenn, Ke Hu, Mario Maldonado et al. · Clinical Therapeutics · 2012 · 17 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Pharmacokinetics and Safety of Subcutaneous Pasireotide and Intramuscular Pasireotide Long-acting Release in Chinese Male Healthy Volunteers: A Phase I, Single-center, Open-label, Randomized Study

Xia Chen, Guoxiang Shen, Ji Jiang et al. · Clinical Therapeutics · 2014 · 15 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15